Zacks Research Has Pessimistic View of Medifast Q2 Earnings

Medifast, Inc. (NYSE:MED) – Analysts at Zacks Research reduced their Q2 2025 earnings per share estimates for Medifast in a report released on Monday, November 25th. Zacks Research analyst A. Mohta now anticipates that the specialty retailer will post earnings of $0.29 per share for the quarter, down from their prior estimate of $0.37. The consensus estimate for Medifast’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Medifast’s Q3 2025 earnings at $0.34 EPS, Q4 2025 earnings at $0.38 EPS, Q1 2026 earnings at $0.42 EPS and Q2 2026 earnings at $0.43 EPS.

Medifast (NYSE:MED) last released its quarterly earnings data on Monday, November 4th. The specialty retailer reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.50. The company had revenue of $140.16 million for the quarter, compared to analyst estimates of $135.45 million. Medifast had a return on equity of 15.98% and a net margin of 1.09%. During the same quarter in the previous year, the company posted $2.12 earnings per share.

Separately, DA Davidson raised Medifast from an “underperform” rating to a “neutral” rating and upped their price target for the company from $16.50 to $17.00 in a research note on Tuesday, November 5th.

Medifast Stock Performance

NYSE MED opened at $19.44 on Wednesday. The stock’s fifty day moving average is $18.49 and its two-hundred day moving average is $19.83. The firm has a market capitalization of $212.67 million, a P/E ratio of 29.45 and a beta of 1.13. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.55 and a current ratio of 3.11. Medifast has a fifty-two week low of $17.07 and a fifty-two week high of $76.42.

Hedge Funds Weigh In On Medifast

Several large investors have recently modified their holdings of MED. Acadian Asset Management LLC lifted its stake in shares of Medifast by 2,000.1% in the 2nd quarter. Acadian Asset Management LLC now owns 338,228 shares of the specialty retailer’s stock valued at $7,376,000 after purchasing an additional 322,123 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Medifast by 117.5% in the 2nd quarter. AQR Capital Management LLC now owns 389,951 shares of the specialty retailer’s stock valued at $8,509,000 after buying an additional 210,669 shares during the period. Federated Hermes Inc. raised its holdings in shares of Medifast by 415.1% in the 2nd quarter. Federated Hermes Inc. now owns 215,090 shares of the specialty retailer’s stock valued at $4,693,000 after buying an additional 173,337 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Medifast by 20.3% in the 2nd quarter. Renaissance Technologies LLC now owns 958,610 shares of the specialty retailer’s stock valued at $20,917,000 after buying an additional 161,487 shares during the period. Finally, Millennium Management LLC raised its holdings in shares of Medifast by 37.8% in the 2nd quarter. Millennium Management LLC now owns 469,216 shares of the specialty retailer’s stock valued at $10,238,000 after buying an additional 128,719 shares during the period. Institutional investors and hedge funds own 95.51% of the company’s stock.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.